Post de Pfizer

Really great event today in our NYC office celebrating Pride month.

Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine. They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs. Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you. #CTD2024

Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual

At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer. In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value. Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors. #LetsOutdoCancer

Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.   To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu

The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well. #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez

Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. Meet Kathleen at LetsOutdoCancer.com.  #Cancer #CancerResearch #Oncology

Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years.  #womeninstem